公开(公告)号：US20220298207A1

公开(公告)日：2022-09-22

申请号：US17698531

申请日：2022-03-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K39/00 ,  A61K38/17 ,  C07K7/06 ,  C12N9/64 ,  C12N5/0783

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20220273783A1

公开(公告)日：2022-09-01

申请号：US17734997

申请日：2022-05-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00 ,  G16B25/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220257736A1

公开(公告)日：2022-08-18

申请号：US17721573

申请日：2022-04-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00 ,  G16B25/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220249633A1

公开(公告)日：2022-08-11

申请号：US17721655

申请日：2022-04-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K14/47 ,  C12Q1/6886 ,  C12N15/115 ,  C07K7/06 ,  A61P35/00 ,  C07K14/74 ,  G01N33/574 ,  C07K16/30 ,  C12N5/0783 ,  C07K7/08 ,  C07K14/725 ,  C07K16/28

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220249630A1

公开(公告)日：2022-08-11

申请号：US17675530

申请日：2022-02-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/06 ,  G01N33/574 ,  C07K14/47 ,  C12Q1/6886 ,  C12N15/115 ,  C07K7/08 ,  A61P35/00 ,  C07K14/74 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220242925A1

公开(公告)日：2022-08-04

申请号：US17716026

申请日：2022-04-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Valentina GOLDFINGER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  C07K14/74 ,  C12N15/62

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220160851A1

公开(公告)日：2022-05-26

申请号：US17669449

申请日：2022-02-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/06 ,  G01N33/574 ,  C07K14/47 ,  C12Q1/6886 ,  C12N15/115 ,  C07K7/08 ,  A61P35/00 ,  C07K14/74 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220143163A1

公开(公告)日：2022-05-12

申请号：US17581054

申请日：2022-01-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  C12N15/115 ,  G01N33/574 ,  C07K14/725 ,  G01N33/68 ,  C07K14/47 ,  C07K16/30 ,  C12Q1/6886 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220143091A1

公开(公告)日：2022-05-12

申请号：US17581260

申请日：2022-01-21

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/47 ,  C07K14/54 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220135636A1

公开(公告)日：2022-05-05

申请号：US17576714

申请日：2022-01-14

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K39/00 ,  G01N33/574 ,  A61P35/00 ,  A61K35/17 ,  C07K16/30 ,  C12N15/115 ,  C07K16/28 ,  C07K14/74 ,  C12N15/10 ,  C07K14/725 ,  C12N5/0783 ,  C07K7/06 ,  C07K14/54 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.